L-Glutamate is a major excitatory neurotransmitter in the mammalian brain. Excessive stimulation of excitatory amino acid receptors has been implicated in neurodegenerative disorders such as Alzheimers disease (1); hypofunction of the glutamate system may be involved in schizophrenic-like disorders (2). Three distinct pharmacological classes of glutamate receptors have been identified which reflect the actions of the relatively selective agonists kainate, quisqualate and N-methyl-D-aspartate (NMDA).
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Recent findings (3) suggest that drugs such as phencyclidine (PCP) and the PCP analog TCP bind either to an allosteric NMDA site or possibly t o the open channel itself. These findings have created a renewed interest developing a radiolabeled PCP-like compound for mapping NMDA-linked glutamate receptors in the mammalian brain by PET.
[18F]Labeled analogs of PCP (1) are currently under investigation in our laboratories for imaging NMDA-type glutamate receptors in brain. This paper presents our preliminary efforts aimed at: 1) determining which position(s) fluorine can be incorporated in the PCP molecule without adversely affecting i s PCP-like potency; 2) developing rapid synthetic methods for incorporating 18F (t% = 110 min) into these compounds for use in in vivo mapping of the glutamate receptor complex by PET. We have shown that 3-a&1o-4-fluoroPCP (2) retains the high binding affinity and pharmaco ogical potency of 3-aminoPCP (2) 3. Kemp, J.A., Foster, A.C. and Wong, E.H., TINS, lo, 294, (1987) .
